--- title: "Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday" type: "News" locale: "en" url: "https://longbridge.com/en/news/303964899.md" description: "Wall Street analysts adjusted outlooks for several stocks. Regeneron Pharmaceuticals (REGN) saw its price target raised to $1,030 by B of A Securities. Mohawk Industries (MHK) and CrowdStrike (CRWD) were upgraded with increased targets. Conversely, PennyMac Financial (PFSI) was downgraded with a cut target, and Coinbase (COIN) saw a significant target reduction. Other changes included adjustments for Acumen, NRX, Netskope, Hyatt, and Biogen." datetime: "2026-11-02T13:26:19.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/303964899.md) - [en](https://longbridge.com/en/news/303964899.md) - [zh-HK](https://longbridge.com/zh-HK/news/303964899.md) generator: "portal-rs" --- # Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. - BTIG cut the price target for **Acumen Pharmaceuticals Inc** (NASDAQ:ABOS) from $8 to $1. BTIG analyst Thomas Shrader maintained a Buy rating. Acumen Pharmaceuticals shares closed at $0.21 on Friday. See how other analysts view this stock. - Keefe, Bruyette & Woods slashed **PennyMac Financial Services Inc** (NYSE:PFSI) price target from $100 to $80. Keefe, Bruyette & Woods analyst George Bose downgraded the stock from Outperform to Market Perform. PennyMac Financial shares closed at $62.92 on Friday. See how other analysts view this stock. - Ascendiant Capital raised price target for **NRX Pharmaceuticals In**c (NASDAQ:NRXP) from $50 to $51. Ascendiant Capital analyst Edward Woo maintained a Buy rating. NRX Pharmaceuticals shares closed at $2.27 on Friday. See how other analysts view this stock. - B of A Securities boosted the price target for **Regeneron Pharmaceuticals Inc** (NASDAQ:REGN) from $908 to $1,030. B of A Securities analyst Tazeen Ahmad maintained a Buy rating. Regeneron Pharmaceuticals shares closed at $927.89 on Friday. See how other analysts view this stock. - Evercore ISI Group raised **Mohawk Industries Inc** (NYSE:MHK) price target from $129 to $171. Evercore ISI Group analyst Stephen Kim upgraded the stock from In-Line to Outperform. Mohawk Industries shares closed at $139.41 on Friday. See how other analysts view this stock. - Deutsche Bank increased **Crowdstrike Holdings Inc** (NASDAQ:CRWD) price target from $240 to $300. Deutsche Bank analyst Brad Zelnick upgraded the stock from Hold to Buy. Crowdstrike shares closed at $250.43 on Friday. See how other analysts view this stock. - BTIG raised **Netskope Inc** (NASDAQ:NTSK) price target from $22 to $30. BTIG analyst Gray Powell maintained a Buy rating. Netskope shares closed at $24.30 on Friday. See how other analysts view this stock. - Morgan Stanley cut the price target for **Coinbase Global Inc** (NASDAQ:COIN) from $258 to $120. Morgan Stanley analyst Michael Cyprys downgraded the stock from Equal-Weight to Underweight. Coinbase shares closed at $143.54 on Friday. See how other analysts view this stock. - Baird raised **Hyatt Hotels Corporatio**n (NYSE:H) price target from $188 to $194. Baird analyst Michael Bellisario maintained a Neutral rating. Hyatt shares closed at $180.57 on Friday. See how other analysts view this stock. - HC Wainwright & Co. raised **Biogen Inc** (NASDAQ:BIIB) price target from $251 to $270. HC Wainwright & Co. analyst Ananda Ghosh maintained a Buy rating. Biogen shares closed at $253.62 on Friday. See how other analysts view this stock. Considering buying REGN stock? Here’s what analysts think: *Photo via Shutterstock* ### Related Stocks - [ABOS.US](https://longbridge.com/en/quote/ABOS.US.md) - [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md) - [COIN.US](https://longbridge.com/en/quote/COIN.US.md) - [CRWD.US](https://longbridge.com/en/quote/CRWD.US.md) - [H.US](https://longbridge.com/en/quote/H.US.md) - [MHK.US](https://longbridge.com/en/quote/MHK.US.md) - [NRXP.US](https://longbridge.com/en/quote/NRXP.US.md) - [NTSK.US](https://longbridge.com/en/quote/NTSK.US.md) - [PFSI.US](https://longbridge.com/en/quote/PFSI.US.md) - [REGN.US](https://longbridge.com/en/quote/REGN.US.md) - [ATC.US](https://longbridge.com/en/quote/ATC.US.md) - [COIA.US](https://longbridge.com/en/quote/COIA.US.md) - [COIG.US](https://longbridge.com/en/quote/COIG.US.md) - [COIO.US](https://longbridge.com/en/quote/COIO.US.md) - [COIW.US](https://longbridge.com/en/quote/COIW.US.md) - [COIX.US](https://longbridge.com/en/quote/COIX.US.md) - [CONI.US](https://longbridge.com/en/quote/CONI.US.md) - [CONL.US](https://longbridge.com/en/quote/CONL.US.md) - [CONX.US](https://longbridge.com/en/quote/CONX.US.md) - [CONY.US](https://longbridge.com/en/quote/CONY.US.md) - [COYY.US](https://longbridge.com/en/quote/COYY.US.md) - [CRWC.US](https://longbridge.com/en/quote/CRWC.US.md) - [CRWL.US](https://longbridge.com/en/quote/CRWL.US.md) - [FIAT.US](https://longbridge.com/en/quote/FIAT.US.md) - [ICOI.US](https://longbridge.com/en/quote/ICOI.US.md) - [LMBO.US](https://longbridge.com/en/quote/LMBO.US.md) - [REKT.US](https://longbridge.com/en/quote/REKT.US.md) - [07711.HK](https://longbridge.com/en/quote/07711.HK.md) - [09311.HK](https://longbridge.com/en/quote/09311.HK.md) ## Related News & Research - [Biogen has 'returned to growth,' says CEO — what to know about its report](https://longbridge.com/en/news/303428637.md) - [These Analysts Increase Their Forecasts On Biogen After Upbeat Q3 Results](https://longbridge.com/en/news/303560479.md) - [Regeneron hits 52-week high after “standout” Q3](https://longbridge.com/en/news/303793362.md) - [These Analysts Raise Their Forecasts On Regeneron Pharmaceuticals After Upbeat Q3 Results](https://longbridge.com/en/news/303968582.md) - [Wedbush maintains Biogen at Neutral, raises price target to $225 from $212](https://longbridge.com/en/news/303592813.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**